mercoledì, Aprile 17, 2024

Proteasome anchors to neuronal membranes to become a signaling platform: moonlightner or hidden deceiver?

Within the nervous system, the proteasome system (PROS) has...

Intelligenza Artificiale al servizio dell’oncologia (II): adesso è il turno dei tumori cerebrali

Introduzione I tumori al cervello, sebbene rari, rappresentano una sfida...

Osteoarthritis on the chip: hyaluronate leads to diagnosis

For the first time, scientists at Wake Forest Baptist Medical Center have been able to measure a specific molecule indicative of osteoarthritis and a number of other inflammatory diseases using a newly developed technology. This preclinical study used a solid-state nanopore sensor as a tool for the analysis of hyaluronic acid (HA). HA is a naturally occurring molecule that is involved in tissue hydration, protection of cartilages from inflammation and joint lubrication in the body. Its abundance and size distribution in biological fluids is recognized as an indicator of inflammation, leading to osteoarthritis and other chronic inflammatory diseases. It can also serve as an indicator of how far the disease has progressed. The study, which is published in the current issue of Nature Communications, was led by Drs. Adam Hall and Elaheh Rahbar of Wake Forest Baptist, and conducted in collaboration with scientists at Cornell University and the University of Oklahoma.

In the study, the team first employed synthetic HA polymers to validate the measurement approach. They then used the platform to determine the size distribution of as little as 10 nanograms of HA extracted from the synovial fluid of a horse model of osteoarthritis. The measurement approach consists of a microchip with a single hole or pore in it that is a few nanometers wide – about 5,000 times smaller than a human hair. This is small enough that only individual molecules can pass through the opening, and as they do, each can be detected and analyzed. By applying the approach to HA molecules, the researchers were able to determine their size one-by-one. HA size distribution changes over time in osteoarthritis, so this technology could help better assess disease progression. The researchers hope to conduct their next study in humans, and then extend the technology with other diseases where HA and similar molecules play a role, including traumatic injuries and cancer.

Lead author Adam R. Hall, PhD, assistant professor of Biomedical engineering at Wake Forest School of Medicine, explained: “The most widely used method is gel electrophoresis, which is slow, messy, semi-quantitative, and requires a lot of starting material. Other technologies include mass spectrometry and size-exclusion chromatography, which are expensive and limited in range, and multi-angle light scattering, which is non-quantitative and has limited precision. By using a minimally invasive procedure to extract a tiny amount of fluid, as example from the knee, we may be able to identify the disease or determine how far it has progressed, which is valuable information for doctors in determining appropriate treatments. Our results established a new, quantitative method for the assessment of a significant molecular biomarker that bridges a gap in the conventional technology. The sensitivity, speed and small sample requirements of this approach, make it attractive as the basis for a powerful analytic tool with distinct advantages over current assessment technologies”.


  • Edited by Dr. Gianfrancesco Cormaci, PhD, specialist in Clinical Biochemistry.

Scientific references

Quilliot J et al. Semin Arthritis Rheum. 2019 Feb 8.

Rivas F et al., Hall AR. Nat Commun. 2018; 9(1):1037. 

Santer V et al. Dermatol Surg. 2019; 45(1):108-116.





Don't miss

Dott. Gianfrancesco Cormaci
Dott. Gianfrancesco Cormaci
Laurea in Medicina e Chirurgia nel 1998, specialista in Biochimica Clinica dal 2002, ha conseguito dottorato in Neurobiologia nel 2006. Ex-ricercatore, ha trascorso 5 anni negli USA alle dipendenze dell' NIH/NIDA e poi della Johns Hopkins University. Guardia medica presso la casa di Cura Sant'Agata a Catania. In libera professione, si occupa di Medicina Preventiva personalizzata e intolleranze alimentari. Detentore di un brevetto per la fabbricazione di sfarinati gluten-free a partire da regolare farina di grano. Responsabile della sezione R&D della CoFood s.r.l. per la ricerca e sviluppo di nuovi prodotti alimentari, inclusi quelli a fini medici speciali.

Glifosato: il pesticida che “contamina” la nostra salute alterando il microbiota intestinale

Depressione e fibromialgia da glifosato: focus sul microbiota L’esposizione a sostanze chimiche come i pesticidi potrebbe anche portare a disturbi depressivi, poiché potrebbe causare anomalie...

How emotions directly and indirectly influence cancer: the first systematic study

"The relationship between a person's emotional state and cancer has been demonstrated in the past, but mainly in relation to negative feelings such as...

Celiachia e microbiota: essere o non essere?

La celiachia (CD) è un disturbo cronico immuno-mediato innescato dall'ingestione di glutine in individui geneticamente predisposti. Il glutine è una proteina complessa costituita da...